Cargando…

Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%

Olopatadine is an antihistamine and mast cell stabilizer used for treating allergic conjunctivitis. Olopatadine 0.7% has been recently approved for daily dosing in the US, which supersedes the previously approved 0.2% strength. The objective of this analysis was to characterize patients who have bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fidler, Matthew L., Ogundele, Abayomi, Covert, David, Sarangapani, Ramesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061088/ https://www.ncbi.nlm.nih.gov/pubmed/29680872 http://dx.doi.org/10.1007/s10928-018-9588-7

Ejemplares similares

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

364 Zero Itch in Eyes Treated With Olopatadine Hydrochloride Ophthalmic Solution, 0.2% in Bilateral Conjunctival Allergen Challenge Studies
por: Blaiss, Michael S., et al.
Publicado: (2012)

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
por: Ackerman, Stacey, et al.
Publicado: (2013)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
por: Epstein, Arthur B, et al.
Publicado: (2009)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Maintenance of remission with low-dose olopatadine hydrochloride for itch in well-controlled chronic urticaria
por: Makino, Teruhiko, et al.
Publicado: (2012)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
por: Schnober, Dietmar, et al.
Publicado: (2010)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

Magnetocapacitance in La(0.7)Sr(0.3)MnO(3)/Pb(Zr(0.2)Ti(0.8))O(3)/La(0.7)Sr(0.3)MnO(3) multiferroic heterostructures
por: Hrib, Luminita M., et al.
Publicado: (2017)

Assessment of the efficacy of olopatadine 0.1% in the treatment of vernal keratoconjunctivitis in terms of clinical improvement based on total ocular symptom score and ocular surface disease index
por: Mohan, S, et al.
Publicado: (2023)

Low Conductivity Decay of Sn–0.7Cu–0.2Zn Photovoltaic Ribbons for Solar Cell Application
por: Chen, Kuan-Jen, et al.
Publicado: (2019)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

Rb/Cs-Modified P2 Na(0.7)Mn(0.8)Mg(0.2)O(2): Application in Sodium-Ion Batteries
por: Sehrawat, Divya, et al.
Publicado: (2019)

Effects of Process Parameters on Bond Properties of Ag-2.35Au-0.7Pd-0.2Pt-0.1Cu Alloy Wire
por: Zhou, Hongliang, et al.
Publicado: (2023)

Enhanced Energy Storage Performance and Efficiency in Bi(0.5)(Na(0.8)K(0.2))(0.5)TiO(3)-Bi(0.2)Sr(0.7)TiO(3) Relaxor Ferroelectric Ceramics via Domain Engineering
por: Pattipaka, Srinivas, et al.
Publicado: (2023)

Thickness-dependent electrocaloric effect in mixed-phase Pb(0.87)Ba(0.1) La(0.02)(Zr(0.6)Sn(0.33)Ti(0.07))O(3) thin films
por: Correia, T. M., et al.
Publicado: (2016)

Stabilization by Configurational Entropy of the Cu(II) Active Site during CO Oxidation on Mg(0.2)Co(0.2)Ni(0.2)Cu(0.2)Zn(0.2)O
por: Fracchia, Martina, et al.
Publicado: (2020)

Is configurational entropy the main stabilizing term in rock-salt Mg(0.2)Co(0.2)Ni(0.2)Cu(0.2)Zn(0.2)O high entropy oxide?
por: Fracchia, Martina, et al.
Publicado: (2022)

Synthesis and Ultrahigh Pressure Compression of High-Entropy Boride (Hf(0.2)Mo(0.2)Nb(0.2)Ta(0.2)Zr(0.2))B(2) to 220 GPa
por: Iwan, Seth, et al.
Publicado: (2022)

Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2023)

Vertically aligned nanocomposite (BaTiO(3))(0.8) : (La(0.7)Sr(0.3)MnO(3))(0.2) thin films with anisotropic multifunctionalities
por: Gao, Xingyao, et al.
Publicado: (2020)

Multiferroic La(0.2)Pb(0.7)Fe(12)O(19) ceramics: Ferroelectricity, ferromagnetism and colossal magneto-capacitance effect
por: Tan, Guo-Long, et al.
Publicado: (2016)

High-Entropy Perovskites as Multifunctional Metal Oxide Semiconductors: Synthesis and Characterization of (Gd(0.2)Nd(0.2)La(0.2)Sm(0.2)Y(0.2))CoO(3)
por: Krawczyk, Paweł A., et al.
Publicado: (2020)

Polysubstituted High-Entropy [LaNd](Cr(0.2)Mn(0.2)Fe(0.2)Co(0.2)Ni(0.2))O(3) Perovskites: Correlation of the Electrical and Magnetic Properties
por: Zhivulin, Vladimir E., et al.
Publicado: (2021)

Anisotropic Properties of Epitaxial Ferroelectric Lead-Free 0.5[Ba(Ti(0.8)Zr(0.2))O(3)]-0.5(Ba(0.7)Ca(0.3))TiO(3) Films
por: Cucciniello, Nicholas, et al.
Publicado: (2023)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán, Leopoldo Martín, et al.
Publicado: (2012)

Sams teach yourself Scratch 2.0 in 24 hours
por: Warner, Timothy L
Publicado: (2014)

Sams Teach Yourself C# 5.0 in 24 Hours
por: Dorman, Scott
Publicado: (2012)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Multiprincipal Component P2-Na(0.6)(Ti(0.2)Mn(0.2)Co(0.2)Ni(0.2)Ru(0.2))O(2) as a High-Rate Cathode for Sodium-Ion Batteries
por: Yang, Lufeng, et al.
Publicado: (2020)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

A Promising High-Entropy Thermal Barrier Material with the Formula (Y(0.2)Dy(0.2)Ho(0.2)Er(0.2)Yb(0.2))(3)Al(5)O(12)
por: Li, Zhanqiang, et al.
Publicado: (2022)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Effect of Poling on Multicatalytic Performance of 0.5Ba(Zr(0.2)Ti(0.8))O(3)-0.5(Ba(0.7)Sr(0.3))TiO(3) Ferroelectric Ceramic for Dye Degradation
por: Gaur, Akshay, et al.
Publicado: (2022)

Influence of Grain Size on Dielectric Behavior in Lead-Free 0.5 Ba(Zr(0.2)Ti(0.8))O(3)–0.5 (Ba(0.7)Ca(0.3))TiO(3) Ceramics
por: Ene, Vladimir Lucian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_15n24d5u4nq7ejdbim305jol9l